A recent randomized controlled trial evaluating the use of Abbots’ TriClip system for transcatheter edge-to-edge repair (TEER) of tricuspid valve in patients with severe tricuspid regurgitation (TR) showed improvements in quality of life and safety at 30 days. Results were presented at the Transcatheter Cardiovascular Therapeutics 2023 congress and revealed that patients experienced sustained TR reduction and improved quality of life after one year. The trial included a randomized arm of patients expected to achieve TR improvement, as well as a single-arm cohort treated with the TriClip device. While the single-arm cohort had higher mortality and hospitalization rates, results have expanded the potential pool of candidates for TriClip therapy. This suggests the importance of further research into tricuspid valve treatments.
Source link
Transcatheter Tricuspid Repair Improved Quality of Life
